









Markets
/
Stocks
/
nasdaq-prok
/

ProKidney Corp

PROK

View Detailed Chart

2.820USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

365.29MMarket Cap

LossP/E TTM



ProKidney Corp

2.820

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

+1.81%

5 Days

-14.29%

1 Month

+342.56%

6 Months

+81.94%

Year to Date

+66.86%

1 Year

+37.56%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 7 analysts

BUY

Current Rating

5.600

Target Price

98.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

ProKidney Corp

PROK

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(3)

Buy(4)

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.323

Neutral

RSI(14)

53.071

Neutral

STOCH(KDJ)(9,3,3)

22.538

Neutral

ATR(14)

0.437

Low Volatility

CCI(14)

-103.388

Sell

Williams %R

85.057

Oversold

TRIX(12,20)

2.573

Sell

StochRSI(14)

32.358

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.826

Sell

MA10

3.017

Sell

MA20

3.301

Sell

MA50

1.777

Buy

MA100

1.307

Buy

MA200

1.498

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).

Ticker SymbolPROK

CompanyProKidney Corp

CEODr. Bruce Culleton, M.D.

Websitehttps://prokidney.com/